No information is available on the clinical use of pazopanib during breastfeeding. Because pazopanib is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 31 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during pazopanib therapy and for 2 weeks after the final dose.